AGFA HealthCare
MORTSEL, BELGIUM / ACCESSWIRE / June 10, 2024 / AGFA HealthCare is thrilled to announce a significant new deal with Alliance Medical to implement an advanced cloud-based solution across all of Alliance Medical's UK sites. Powered by the AGFA HealthCare Enterprise Imaging Platform, this state-of-the-art approach supports Alliance Medical UK's Future Unified Diagnostic Information System (FUDIS) project. This project aims to streamline the entire patient pathway, establishing a robust and lasting partnership between AGFA HealthCare and Alliance Medical.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Deployment of the solution will begin later in 2024, with a phased implementation approach to ensure a smooth and efficient transition of all imaging services across 120 sites for all of Alliance Medical's UK community diagnostic centres (CDCs), static imaging sites for PET-CT, MRI, CT and other imaging modalities and its extensive fleet of mobile, modular and relocatable units, delivering over 400,000 annual exams.
Efficiency gains, clinical effectiveness, and collaboration workflows
Alliance Medical has been a trusted partner to the NHS for 30 years, providing diagnostic imaging solutions to patients throughout the UK. This partnership with AGFA HealthCare will play a pivotal role in achieving the strategic vision for Alliance Medical's UK business to provide long-term, sustainable diagnostic imaging solutions on behalf of the NHS and other partners.
"The ground-breaking partnership between Alliance Medical and AGFA HealthCare will play a key role in enabling us to achieve our strategic vision, on behalf of our patients and stakeholders, and will support our commitment to integrating diagnostics into existing care pathways. AGFA HealthCare's solution really led from the front, and the digital ecosystem they brought together will deliver the experience, knowledge and innovation needed to create a complete cloud-based solution which covers the entire end-to-end patient pathway," says Pete Winchester, UK Managing Director at Alliance Medical.
"We are delighted to further strengthen our partnership with Alliance Medical Group and the relationship with Alliance Medical UK, which is an integral part of the health economy in the UK and beyond. Combining that bond with our close collaboration with our market-leading partners will enable us to jointly deliver a luminary solution that brings together each of our leading technologies: enterprise imaging, clinical decision support, complex workflow orchestration and advanced augmented intelligence. These will run through the heart of the solution to enable clinicians to deliver outcomes for patients and an exceptional user experience that is rich in efficiency gains," says Roberto Anello, Regional President for Northern Europe for AGFA HealthCare.
Transformative Technologies Delivering an Exceptional User Experience
- The solution includes the AGFA HealthCare Enterprise Imaging Platform, with Shared Workflow and the XERO® Exchange Network (XEN):
- Designed around scalability, connectivity and clinical collaboration, Enterprise Imaging enables near-real-time access to images and delivers powerful tools and features for diagnosis, collaboration, workflow and more. By facilitating "imaging without barriers," it supports patient and clinician work-life balance, as well as the balancing of radiologists' tasks and reporting workloads between different organisations.
- Fully embedded artificial intelligence and advanced visualisation tools for molecular imaging all support complex clinical workflows by providing a solution that is readily available regardless of location and time.
- The Enterprise Imaging Collaborator tool and the new Shared Workflow feature offer completely new ways of managing activity to match reporting capacity with demand, improve clinician collaboration through multi-author workflows, and align unified ‘specialist' Reporting Worklists with scarce reporting skills. The embedded XERO® application enables clinical teams to engage and share information. Enterprise Imaging is now entering the era of streaming clients capable of displaying large amounts of data in near real-time.
- AGFA HealthCare Enterprise Imaging is powered by Amazon Web Services (AWS) cloud services, which gives Alliance Medical access to the security, reliability and scalability of the public cloud.
The platform is complemented for referrals by two market-leading solutions, including:
- xWave Technologies' Smart Referring, an advanced portal for referring clinicians, integrated with Enterprise Imaging XERO®. xWave Smart Referring incorporates a dynamic Clinical Decision Support system which supports clinicians in accessing the most appropriate diagnostic test for their patients. Innovations such as the Smart Vetting workflow also reduce workloads for administrative and clinical staff, while improving patient safety and care.
- Streets Heaver's Compucare® PAS/EPR (patient administration system/electronic patient record): This market-leading solution is designed for private patient workflows as well as managing NHS contracts and eReferrals. It supports all clinical activity types from general clinic consultations to diagnostic imaging workflows, as well as other non-imaging diagnostic services. Patient engagement is supported through the Patient Portal.
About AGFA HealthCare
At AGFA HealthCare, we are transforming the delivery of care - supporting healthcare professionals across the globe with secure, effective, and sustainable imaging data management. As a company, we are dedicated to our customers, and we have harnessed a value framework of Mission, Vision, and Customer Delivery Principles into our routine operations. Through these principles, we commit a consistent high-yield code of conduct to our associates - channelling our experience and aspirations to all our stakeholders. Our Empowerer profile supports our focus on creating an exceptional experience through the power of technology and is an integral foundation of our company standards. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.
AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO® is a registered trademark of AGFA HealthCare N.V. All rights reserved. Compucare is a registered trademark of Streets Heaver Computer Systems Ltd. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.
Contact Information
Buse Kayar
buse.kayar@issuerdirect.com
SOURCE: AGFA HealthCare
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom